ARK Genomic Revolution ETF (ARKG) saw an increase in institutional investors’ interest during the first quarter. Park Avenue Securities LLC raised its stake in ARKG by 14.0%, owning 11,667 shares valued at $336,000. Other firms like Cooper Financial Group, NBC Securities Inc., Hilltop Holdings Inc., Kovack Advisors Inc., and Principal Securities Inc. also added to their positions in ARKG.
Despite the investments, ARKG’s stock price decreased by 1.1% to $23.48 on Monday. The fund, managed by ARK, focuses on companies in the genomics industry and was launched on Oct 31, 2014.
Investors can track ARKG’s performance through MarketBeat.com’s daily email newsletter, which provides news and ratings for ARK Genomic Revolution ETF and related companies.